UNITED STATES SECURITIES AND EXCHANGE COMMISSION August 22, 2018

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

Prothena Corporation plc

File No. 001-35676- CF#36367

Prothena Corporation plc submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed on May 9, 2018, as amended on August 17, 2018.

Based on representations by Prothena Corporation plc that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.1(a)	through May 9, 2021
Exhibit 10.1(b)	through May 9, 2021
Exhibit 10.2	through May 9, 2021
Exhibit 10.3	through May 9, 2021

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary